VANOS SUMMARY
VANOS™
(fluocinonide) Cream, 0.1%
VANOS™ (fluocinonide) Cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide has the chemical name 6 alpha, 9 alpha-difluoro-11 beta, 21-dihydroxy-16 alpha, 17 alpha-isopropylidenedioxypregna-1, 4-diene-3,20-dione 21-acetate.
VANOS™ (fluocinonide) Cream, 0.1%, is a corticosteroid indicated for treatment of plaque-type psoriasis affecting up to 10% body surface area (BSA). Use in patients under 18 years of age is not recommended because safety has not been established (See PRECAUTIONS–Pediatric Use.)
Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 60 g/week because the safety of VANOS™ Cream for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Therapy should be discontinued when control of psoriasis has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
|
NEWS HIGHLIGHTSMedia Articles Related to Vanos (Fluocinonide Topical)
International Psoriasis Council Hosts Second Educational Symposium To Increase Global Knowledge Of Psoriasis
Source: Dermatology News From Medical News Today [2009.11.18]
Beginning Thursday, Nov. 19, 2009, the International Psoriasis Council (IPC) will host its second symposium at Baylor University Medical Center in Dallas. The two-day conference brings together dermatologists from Asia, Eastern Europe and Spain to elevate the global understanding of psoriasis and its treatment. Sessions will be facilitated by leading dermatologists and nurses dedicated to psoriasis management and research.
Psoriatic arthritis common in people with psoriasis (Reuters)
Source: Y! Health Arthritis News [2009.11.05]
Reuters - As many as 14 percent of people with psoriasis may also have psoriatic arthritis, research shows.
EADV: Psoriasis Comorbidities May Cut Longevity (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- Psoriasis patients have a substantial comorbidity burden that can reduce life expectancy by 10 years or more, according to data presented here.
EADV: Benefit of Methrotrexate in Psoriasis Will Show Up Early (CME/CE)
Source: MedPage Today Dermatology [2009.10.14]
BERLIN (MedPage Today) -- A suboptimal response to methotrexate at 12 weeks identified psoriasis patients who were unlikely to benefit from continued therapy at higher doses, a retrospective analysis of clinical-trial data showed.
EADV: Anti-TNF Exposure Does Not Rule out TNF Inhibitor for Psoriasis (CME/CE)
Source: MedPage Today Dermatology [2009.10.13]
BERLIN (MedPage Today) -- Prior exposure to anti-tumor necrosis factor (TNF) therapy does not rule out potential benefits from additional anti-TNF therapy for patients with psoriasis, according to data presented here.
Published Studies Related to Vanos (Fluocinonide Topical)
An open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitis. [2006.12]
OBJECTIVE: To assess the potential of a superhigh-potency 0.1% fluocinonide cream to suppress the hypothalamic-pituitary-adrenal (HPA) axis in pediatric patients with atopic dermatitis... CONCLUSIONS: Once-daily treatment with 0.1% fluocinonide cream for 2 weeks does not result in HPA axis suppression under the conditions of this study. Once-daily applications provided similar or better efficacy as twice-daily applications with a lower risk of HPA axis suppression. The frequency of HPA axis suppression is no greater in younger children than in older children. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN71227633.
The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison. [2009.08]
BACKGROUND: This study compared the efficacy of a novel, topical class I synthetic, 0.10% fluocinonide corticosteroid with two other class I corticosteroids and placebo for the treatment of plaque psoriasis... CONCLUSION: The three class I corticosteroid products were comparably effective, numerically and statistically, in clearing the psoriatic plaques. Upon completion of treatment, 60-80% of active-treated sites were clear or almost clear of psoriasis compared to zero with the placebo.
Case report: Fluocinonide-induced perioral dermatitis in a patient with psoriasis. [2009.03.15]
Topical corticosteroids are the primary treatment for psoriasis. A patient with psoriasis being treated with topical fluocinonide for lesions on the extremities developed an erythematous facial eruption consistent with perioral dermatitis... The potential for drug-induced perioral dermatitis should be considered in psoriasis patients treated with potent topical corticosteroids.
A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. [2008.06]
To compare the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05%, 20 participants with corticosteroid-responsive dermatoses were randomly assigned to receive fluocinonide cream 0.1% on one arm and clobetasol propionate cream 0.05% on the other arm... However, neither drug caused significant clinical signs of atrophy.
In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. [2008.01]
PURPOSE: Prolonged topical corticosteroid use is often associated with atrophic skin changes. This trial compared signs of skin atrophy related to 3 super-high-potency corticosteroids: fluocinonide 0.1% cream, clobetasol propionate 0.05% cream, and 0.05% foam... CONCLUSIONS: Fluocinonide cream has a lower potential to produce atrophic changes of the skin than either clobetasol cream or clobetasol propionate foam.
Clinical Trials Related to Vanos (Fluocinonide Topical)
VANOS Cream and Skin Barrier Function [Recruiting]
The purpose of this study is to determine the effect of short-term therapy using "VANOS
Cream," a super-potent topical steroid cream on skin barrier function in patients with
atopic dermatitis. This cream is already approved for this indication, but the
investigators will further examine its effects on the skin barrier. This cream is a novel
formulation of fluocinonide designed to enhance compliance with a cream base, but have the
skin barrier repair properties of an ointment.
Sorafenib-induced Hand- Foot Skin Reaction Treatment [Recruiting]
|
